Publications by authors named "R H A Weijer"

Ambulatory measurements of trunk accelerations can provide valuable insight into the amount and quality of daily life activities. Such information has been used to create models to identify individuals at high risk of falls. However, external validation of such prediction models is lacking, yet crucial for clinical implementation.

View Article and Find Full Text PDF

Cancer Core Europe brings together the expertise, resources, and interests of seven leading cancer institutes committed to leveraging collective innovation and collaboration in precision oncology. Through targeted efforts addressing key medical challenges in cancer and partnerships with multiple stakeholders, the consortium seeks to advance cancer research and enhance equitable patient care.

View Article and Find Full Text PDF

Purpose: Hodgkin lymphoma (HL) survivors are at increased risk of cardiovascular disease (CVD) due to former lymphoma treatment. In 2013, cardiovascular screening for 5-year HL survivors according to national guidelines was implemented in Dutch survivorship clinics. We aim to assess the following: (1) adherence to screening guidelines and (2) the yield of (risk factors for) CVD in the screening program.

View Article and Find Full Text PDF

Purpose: Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Studies in childhood cancer survivors have shown that doxorubicin exposure may also increase BC risk. Although doxorubicin is the cornerstone of HL chemotherapy, the association between doxorubicin and BC risk has not been examined in HL survivors treated at adult ages.

View Article and Find Full Text PDF
Article Synopsis
  • The study highlights that five-year survivors of diffuse large B-cell lymphoma (DLBCL) are at a higher risk of developing subsequent malignant neoplasms (SMNs), particularly among younger patients and those treated with higher doses of certain chemotherapy drugs.
  • After a median follow-up of 13.8 years, 321 out of 2373 survivors developed SMNs, with significant increases noted for lung and gastrointestinal cancers.
  • The research indicates that treatment including rituximab may lower the risk of certain cancers, underscoring the importance of long-term monitoring of DLBCL survivors and the need for further studies to assess risks associated with newer treatments.
View Article and Find Full Text PDF